title: HER2-Positive Metastatic Breast Cancer Patients Receiving Pertuzumab in a Community Oncology Practice Setting: Treatment Patterns and Outcomes.
abstract: BACKGROUND
  Pertuzumab (Perjeta®), a HER2/neu receptor antagonist, was approved by the US Food and Drug Administration in June 2012 for use in the first-line setting for patients with HER2-positive metastatic breast cancer (mBC).
  
  
  OBJECTIVE
  This retrospective study investigated the clinical and demographic characteristics, treatment patterns, safety, and clinical outcomes for patients with HER2-positive mBC who received pertuzumab in the first-line setting in US community oncology practices.
  
  
  METHODS
  Patients with HER2-positive mBC, who initiated pertuzumab within 60 days of mBC diagnosis between June 2012 and June 2014, followed through December 2014, had ≥2 visits within the McKesson Specialty Health/US Oncology Network, and were not on clinical trials during the study period, were eligible. This study utilized iKnowMed electronic health records, Claims Data Warehouse, and Social Security Death Index. Progression-free survival (PFS) was assessed by Kaplan-Meier methods.
  
  
  RESULTS
  A total of 266 patients met the selection criteria. A vast majority of the patients (249/266, 93.6%) received a trastuzumab + pertuzumab + taxane (H + P + T) regimen. The number of patients with prior adjuvant/neoadjuvant therapy was higher than the CLEOPATRA trial, but age (median 57 years) and percentage of visceral disease (74.8%) were similar. The most common adverse events were fatigue (50.8%), diarrhea (44.7%), nausea (35.3%), peripheral neuropathy (33.5%), neutropenia (24.9%), and rash (24.4%). The median PFS was 16.9 months (95% CI 14.2-19.7).
  
  
  CONCLUSIONS
  In this retrospective study of patients with HER2-positive mBC receiving pertuzumab in the first-line setting, most patients were treated with H + P + T. The safety and PFS of H + P + T were consistent with those observed in the pivotal trial.
authors.affiliation: Virginia Cancer Specialists, 8503 Arlington Blvd #400, Fairfax, VA, 22031, USA. Nicholas.robert@USONCOLOGY.com.
authors.forename: Nicholas J
authors.initials: NJ
authors.lastname: Robert
authors.affiliation: Genentech, Inc., South San Francisco, CA, USA.
authors.forename: Hans-Peter
authors.initials: HP
authors.lastname: Goertz
authors.affiliation: McKesson Specialty Health, The Woodlands, TX, USA.
authors.forename: Pooja
authors.initials: P
authors.lastname: Chopra
authors.affiliation: McKesson Specialty Health, The Woodlands, TX, USA.
authors.forename: Xiaolong
authors.initials: X
authors.lastname: Jiao
authors.affiliation: Genentech, Inc., South San Francisco, CA, USA.
authors.forename: Bongin
authors.initials: B
authors.lastname: Yoo
authors.affiliation: Texas Oncology, Austin, TX, USA.
authors.forename: Debra
authors.initials: D
authors.lastname: Patt
authors.affiliation: Genentech, Inc., South San Francisco, CA, USA.
authors.forename: Vincent
authors.initials: V
authors.lastname: Antao